CCTA-Guided PCI
Definition
CCTA-guided PCI is a strategy in which coronary CT angiography and CT-derived fractional flow reserve (FFR-CT), performed before the invasive procedure, are used to plan and guide percutaneous coronary intervention. Planning includes lesion preparation, stent diameter and length, proximal and distal landing zones, optimal angiographic projections and the expected physiological benefit of revascularization. During the procedure, three-dimensional CT reconstructions can be synchronized with angiography, and stent-enhancement imaging can be used for optimization. The strategy moves key decisions upstream, before coronary instrumentation. (sources/CTCA-IVUS-PCI-NEJM-2026, rating: high)
Key Concepts
Rationale
- Intravascular imaging–guided PCI, particularly IVUS, reduces adverse events compared with angiography guidance, but it requires additional coronary instrumentation and provides information only after catheterization has begun.
- Much of PCI strategy is currently decided in the catheterization laboratory in real time. A structured preprocedural plan could allow operators to anticipate complexity and define lesion preparation, stent sizing and projections in advance.
- CCTA provides noninvasive anatomical assessment; FFR-CT adds physiological information and estimates the expected effect of revascularization.
- The potential advantages are better planning, shorter procedures, less contrast and radiation, and improved shared decision-making before catheterization.
The P4 Trial
| Element | Detail |
|---|---|
| Population | 1,105 patients with chronic coronary syndrome or stabilized NSTE-ACS; ≥1 epicardial lesion with diameter stenosis >70% and FFR-CT ≤0.80; reference vessel 2.5–4.0 mm; ≤2 target vessels |
| Exclusions | STEMI, left main disease, prior PCI in target vessel, prior CABG, eGFR ≤30, BMI ≥35, inadequate CCTA quality |
| Comparison | CCTA-guided PCI versus IVUS-guided PCI |
| Primary endpoint | Target-vessel failure (cardiac death, target-vessel MI, ischemia-driven target-vessel revascularization) at 12 months |
| Primary result | 4.1% versus 4.6%; risk difference −0.42 percentage points (95% CI −2.82 to 1.99); P<0.001 for noninferiority; P=0.73 for superiority |
| Noninferiority margin | 4.5 percentage points |
| Procedure duration | 46 versus 63 minutes (median difference −17.0 minutes) |
| Contrast volume | 150 versus 170 mL (median difference −20.0 mL) |
| Radiation exposure | 35.6 versus 38.5 Gy·cm² |
(sources/CTCA-IVUS-PCI-NEJM-2026, rating: high)
Strategy Components
- Preprocedural planning package. Coronary anatomy, lesion and plaque characteristics, calcium burden, myocardial mass at risk and physiological characteristics are summarized into recommendations for lesion preparation, stent diameter and length, landing zones and optimal projections.
- Intraprocedural guidance. 3D CCTA reconstructions are synchronized with the angiographic system using QAngio CT software.
- Elective intravascular imaging is prohibited except for bailout; stent-enhancement imaging is required for optimization.
- The comparator is IVUS-guided PCI, not angiography-guided PCI, which is the more common real-world standard in many centres.
Outcomes and Interpretation
- CCTA-guided PCI was noninferior to IVUS-guided PCI for target-vessel failure at 12 months.
- The individual components were similar: cardiac death 0 versus 2 (0.4%), target-vessel MI 2.9% versus 3.5%, and ischemia-driven target-vessel revascularization 1.4% versus 1.5%.
- The procedure was shorter and used less contrast and radiation with CCTA guidance, despite more frequent use of calcium-modification devices (9.2% versus 3.8%).
- Per-protocol and post hoc analyses were consistent with the intention-to-treat result.
- The trial compared strategies, not imaging methods in isolation; CCTA and IVUS show high agreement on plaque characterization and vessel sizing, but the trial does not establish equivalence between the two.
Applicability
- The strategy requires diagnostic-quality CCTA, FFR-CT analysis and structured procedural planning; it is not transferable to patients with inadequate CT images.
- The trial excluded left main disease, prior CABG, BMI ≥35, severe renal impairment and substantially greater anatomical complexity than the enrolled population.
- Only 4.1% of scans used photon-counting CT; improved spatial resolution and calcium characterization may change feasibility and reproducibility.
- Women comprised 21.7% of the trial population, limiting sex-specific inference.
Relationship to Intravascular Imaging
- IVUS and OCT remain the reference standards for stent optimization and are recommended for complex PCI. (sources/ivus-chip-nejm-2026, rating: high)
- CCTA guidance does not replace intravascular imaging during the procedure; it shifts planning upstream and uses stent-enhancement imaging for post-deployment assessment.
- The choice between strategies may depend on local expertise, CT availability, lesion complexity and the need for intraprocedural imaging to assess stent expansion.
Contradictions / Open Questions
- The comparator was IVUS, not angiography. Most PCI worldwide is angiography-guided, and the trial does not show that CCTA guidance is superior to angiography. Noninferiority to IVUS is a meaningful result, but it leaves the comparison with routine practice untested.
- The noninferiority margin is large relative to the observed event rate. The 4.5-percentage-point margin was set against an anticipated 7.2% event rate; the observed IVUS event rate was 4.6%. The confidence interval permits an absolute benefit of 2.82 points or an excess risk of up to 1.99 points with CCTA guidance.
- Periprocedural MI drives the composite. More than half of primary endpoint events were periprocedural MIs, and troponin was measured systematically after PCI. The result may be sensitive to the definition of periprocedural MI and to how aggressively biomarkers were sampled compared with other trials.
- The trial does not show a clinical advantage. Noninferiority is the headline; superiority was not demonstrated (P=0.73). The benefits are procedural efficiency and resource use, not fewer hard events.
- Generalizability is constrained by selection. Patients with left main disease, prior CABG, severe renal impairment, BMI ≥35 or inadequate CT quality were excluded, and only 21.7% were women.
- The role of FFR-CT is inseparable from the strategy. All patients had FFR-CT ≤0.80, so the trial does not tell us whether anatomical CCTA alone would perform as well or whether FFR-CT is essential to the planning benefit.
- Durability and cost-effectiveness are unknown. The trial followed patients for 12 months; whether the strategy affects long-term outcomes or is cost-effective compared with IVUS or angiography is unresolved.
Connections
- Part of concepts/Intracoronary-Imaging-Guided-PCI — the parent imaging-guidance framework
- concepts/Angiography-Based-Coronary-Physiology — FFR-CT and other physiological assessment tools
- concepts/Complete-Revascularization — the broader revascularization strategy
- concepts/CT-Coronary-Angiography-in-Acute-Chest-Pain — the diagnostic use of CTCA in a different population
- entities/Chronic-Coronary-Disease — the predominant clinical presentation
- entities/Left-Main-Coronary-Disease — excluded from P4 and a distinct high-risk population